Spranger JW, Brill PW, Nishimura G, Superti-Furga A, Unger S. Introduction. In: Spranger JW, Brill PW, Nishimura G, Superti-Furga A, Unger S, editors. Bone dysplasias. New York: Oxford University Press; 2012.

Chapter  Google Scholar 

Geister KA, Camper SA. Advances in skeletal dysplasia genetics. Annu Rev Genomics Hum Genet. 2015;16(1):199–227. https://doi.org/10.1146/annurev-genom-090314-045904.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Dubail J, Brunelle P, Baujat G, Huber C, Doyard M, Michot C, et al. Homozygous loss-of-function mutations in CCDC134 are responsible for a severe form of osteogenesis imperfecta. J Bone Miner Res. 2020. https://doi.org/10.1002/jbmr.4011.

Rafati M, Mohamadhashem F, Hoseini A, Hoseininasab F, Ghaffari SR. A novel ACVR1 mutation detected by whole exome sequencing in a family with an unusual skeletal dysplasia. Eur J Med Genet. 2016;59(6–7):330–6. https://doi.org/10.1016/j.ejmg.2016.05.007.

Article  PubMed  Google Scholar 

Marini JC, Forlino A, Bachinger HP, Bishop NJ, Byers PH, Paepe A, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3(1):17052. https://doi.org/10.1038/nrdp.2017.52.

Article  PubMed  Google Scholar 

Lindahl K, Kindmark A, Rubin CJ, Malmgren B, Grigelioniene G, Soderhall S, et al. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with pamidronate. Bone. 2016;87:11–8. https://doi.org/10.1016/j.bone.2016.02.015.

CAS  Article  PubMed  Google Scholar 

The International For Clinical Densitometry. 2019 ISCD Official Positions – Pediatric. 2019. https://www.iscd.org/official-positions/2019-iscd-official-positions-pediatric/.

Bachrach LK, Gordon CM, Section on Endocrinology. Bone densitometry in children and adolescents. Pediatrics. 2016;138(4). https://doi.org/10.1542/peds.2016-2398.

Zemel BS, Leonard MB, Kelly A, Lappe JM, Gilsanz V, Oberfield S, et al. Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children. J Clin Endocrinol Metab. 2010;95(3):1265–73. https://doi.org/10.1210/jc.2009-2057.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Klein GL. Introduction. In: Klein GL, editor. Bone drugs in pediatrics. New York: Springer; 2014.

Chapter  Google Scholar 

Biggin A, Munns CF. Bisphosphonates in osteogenesis imperfecta. In: Klein GL, editor. Bone drug in pediatrics. New York: Springer; 2014.

Google Scholar 

Russell RG. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2–19. https://doi.org/10.1016/j.bone.2011.04.022.

CAS  Article  PubMed  Google Scholar 

Sbrocchi AM, Forget S, Laforte D, Azouz EM, Rodd C. Zoledronic acid for the treatment of osteopenia in pediatric Crohn’s disease. Pediatr Int. 2010;52(5):754–61. https://doi.org/10.1111/j.1442-200X.2010.03174.x.

CAS  Article  PubMed  Google Scholar 

Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2012;25(5–6):485–91. https://doi.org/10.1515/jpem-2012-0016.

CAS  Article  PubMed  Google Scholar 

Bowden SA, Mahan JD. Zoledronic acid in pediatric metabolic bone disorders. Transl Pediatr. 2017;6(4):256–68. https://doi.org/10.21037/tp.2017.09.10.

Article  PubMed  PubMed Central  Google Scholar 

Otaify GA, Aglan MS, Ibrahim MM, Elnashar M, El Banna RA, Temtamy SA. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study. Osteoporos Int. 2016;27(1):81–92. https://doi.org/10.1007/s00198-015-3216-9.

CAS  Article  PubMed  Google Scholar 

Panigrahi I, Das RR, Sharda S, Marwaha RK, Khandelwal N. Response to zolendronic acid in children with type III osteogenesis imperfecta. J Bone Miner Metab. 2010;28(4):451–5. https://doi.org/10.1007/s00774-009-0149-4.

CAS  Article  PubMed  Google Scholar 

Constantino CS, Krzak JJ, Fial AV, Kruger KM, Rammer JR, Radmanovic K, et al. Effect of bisphosphonates on function and mobility among children with osteogenesis imperfecta: a systematic review. JBMR Plus. 2019;3(10):e10216. https://doi.org/10.1002/jbm4.10216.

Article  PubMed  PubMed Central  Google Scholar 

Li LJ, Zheng WB, Zhao DC, Yu W, Wang O, Jiang Y, et al. Effects of zoledronic acid on vertebral shape of children and adolescents with osteogenesis imperfecta. Bone. 2019;127:164–71. https://doi.org/10.1016/j.bone.2019.06.011.

CAS  Article  PubMed  Google Scholar 

Robinson ME, Trejo P, Palomo T, Glorieux FH, Rauch F. Osteogenesis imperfecta: skeletal outcomes after bisphosphonate discontinuation at final height. J Bone Miner Res. 2019;34(12):2198–204. https://doi.org/10.1002/jbmr.3833.

CAS  Article  PubMed  Google Scholar 

George S, Weber DR, Kaplan P, Hummel K, Monk HM, Levine MA. Short-term safety of zoledronic acid in young patients with bone disorders: an extensive institutional experience. J Clin Endocrinol Metab. 2015;100(11):4163–71. https://doi.org/10.1210/jc.2015-2680.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Sbrocchi AM, Rauch F, Jacob P, McCormick A, McMillan HJ, Matzinger MA, et al. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporos Int. 2012;23(11):2703–11. https://doi.org/10.1007/s00198-012-1911-3.

CAS  Article  PubMed  Google Scholar 

Lim A, Zacharin M, Pitkin J, de Valle K, Ryan MM, Simm PJ. Therapeutic options to improve bone health outcomes in Duchenne muscular dystrophy: zoledronic acid and pubertal induction. J Paediatr Child Health. 2017;53(12):1247–8. https://doi.org/10.1111/jpc.13692.

Article  PubMed  Google Scholar 

Nasomyont N, Hornung LN, Wasserman H. Intravenous bisphosphonate therapy in children with spinal muscular atrophy. Osteoporos Int. 2020;31(5):995–1000. https://doi.org/10.1007/s00198-019-05227-9.

CAS  Article  PubMed  Google Scholar 

Boyce AM, Chong WH, Yao J, Gafni RI, Kelly MH, Chamberlain CE, et al. Denosumab treatment for fibrous dysplasia. J Bone Miner Res. 2012;27(7):1462–70. https://doi.org/10.1002/jbmr.1603.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Eller-Vainicher C, Rossi DS, Guglielmi G, Beltramini GA, Cairoli E, Russillo A, et al. Prompt clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia. Clin Cases Miner Bone Metab. 2016;13(3):253–6. https://doi.org/10.11138/ccmbm/2016.13.3.253.

Article  PubMed  Google Scholar 

Majoor BCJ, Papapoulos SE, Dijkstra PDS, Fiocco M, Hamdy NAT, Appelman-Dijkstra NM. Denosumab in patients with fibrous dysplasia previously treated with bisphosphonates. J Clin Endocrinol Metab. 2019;104(12):6069–78. https://doi.org/10.1210/jc.2018-02543.

Article  PubMed  Google Scholar 

Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P, Schoenau E. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact. 2012;12(3):183–8.

CAS  PubMed  Google Scholar 

Hoyer-Kuhn H, Netzer C, Koerber F, Schoenau E, Semler O. Two years’ experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare Dis. 2014;9(1):145. https://doi.org/10.1186/s13023-014-0145-1.

Article  PubMed  PubMed Central  Google Scholar 

Trejo P, Palomo T, Montpetit K, Fassier F, Sato A, Glorieux FH, et al. Long-term follow-up in osteogenesis imperfecta type VI. Osteoporos Int. 2017;28(10):2975–83. https://doi.org/10.1007/s00198-017-4141-x.

CAS  Article  PubMed  Google Scholar 

Ward L, Bardai G, Moffatt P, Al-Jallad H, Trejo P, Glorieux FH, et al. Osteogenesis imperfecta type VI in individuals from Northern Canada. Calcif Tissue Int. 2016;98(6):566–72. https://doi.org/10.1007/s00223-016-0110-1.

CAS  Article  PubMed  Google Scholar 

Federman N, Brien EW, Narasimhan V, Dry SM, Sodhi M, Chawla SP. Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets. Paediatr Drugs. 2014;16(1):21–8. https://doi.org/10.1007/s40272-013-0051-3.

Article  PubMed  Google Scholar 

Bardakhchyan S, Kager L, Danielyan S, Avagyan A, Karamyan N, Vardevanyan H, et al. Denosumab treatment for progressive skull base giant cell tumor of bone in a 14 year old female - a case report and literature review. Ital J Pediatr. 2017;43(1):32. https://doi.org/10.1186/s13052-017-0353-0.

Article  PubMed  PubMed Central  Google Scholar 

Karras NA, Polgreen LE, Ogilvie C, Manivel JC, Skubitz KM, Lipsitz E. Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl. J Clin Oncol. 2013;31(12):e200–2. https://doi.org/10.1200/JCO.2012.46.4255.

Article  PubMed  PubMed Central  Google Scholar 

Reddy K, Ramirez L, Kukreja K, Venkatramani R. Response to denosumab in 2 children with recurrent giant cell tumor of the bone with pulmonary metastasis. J Pediatr Hematol Oncol. 2019;Publish Ahead of Print. https://doi.org/10.1097/MPH.0000000000001654.

Uday S, Gaston CL, Rogers L, Parry M, Joffe J, Pearson J, et al. Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone. J Clin Endocrinol Metab. 2018;103(2):596–603. https://doi.org/10.1210/jc.2017-02025.

Article  PubMed  Google Scholar 

Bredell M, Rordorf T, Kroiss S, Rucker M, Zweifel DF, Rostetter C. Denosumab as a treatment alternative for central giant cell granuloma: a long-term retrospective cohort study. J Oral Maxillofac Surg. 2018;76(4):775–84. https://doi.org/10.1016/j.joms.2017.09.013.

Article  PubMed  Google Scholar 

Naidu A, Malmquist MP, Denham CA, Schow SR. Management of central giant cell granuloma with subcutaneous denosumab therapy. J Oral Maxillofac Surg. 2014;72(12):2469–84. https://doi.org/10.1016/j.joms.2014.06.456.

Article  PubMed  Google Scholar 

Upfill-Brown A, Bukata S, Bernthal NM, Felsenfeld AL, Nelson SD, Singh A, et al. Use of denosumab in children with osteoclast bone dysplasias: report of three cases. JBMR Plus. 2019;3(10):e10210. https://doi.org/10.1002/jbm4.10210.

Article  PubMed  PubMed Central  Google Scholar 

Kurucu N, Akyuz C, Ergen FB, Yalcin B, Kosemehmetoglu K, Ayvaz M et al. Denosumab treatment in aneurysmal bone cyst: evaluation of nine cases. Pediatr Blood Cancer. 2018;65(4). https://doi.org/10.1002/pbc.26926.

Lange T, Stehling C, Frohlich B, Klingenhofer M, Kunkel P, Schneppenheim R, et al. Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts. Eur Spine J. 2013;22(6):1417–22. https://doi.org/10.1007/s00586-013-2715-7.

Article  PubMed  PubMed Central